John Blankenhorn

John Blankenhorn

InvestorPlace Contributor

Expertise: Biochemistry, biotechnology and pharmaceutical research

John Blankenhorn has been a researcher since 2016 and has years of experience and publications on the topics of biochemistry, biotechnology, and pharmaceutical research. His main interests are the application of biology and biotechnology to our daily lives, as well as the use of Machine Learning and AI to speed up research and development in the life sciences. He currently works at Emory University studying the structural basis of Alzheimer’s Disease.

Recent Articles

The 3 Best Agribusiness Stocks to Buy for June 2023

By John Blankenhorn, InvestorPlace Contributor

People will always need food. Here are the best agribusiness stocks leveraging technology and innovation to bring you the food you need.

3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon

By John Blankenhorn, InvestorPlace Contributor

These three small companies could become gold or lead depending on the outcomes of their clinical trials making them top drug stocks to watch.

3 Solar Stocks to Buy Now or Regret Missing the Next Big Boom

By John Blankenhorn, InvestorPlace Contributor

As nations rush to meet their climate goals, solar power is becoming the energy of choice. And that means big gains for solar stocks.

The 3 Best Biofuel Stocks to Buy Now

By John Blankenhorn, InvestorPlace Contributor

Biofuels are the energy of choice to replace oil, using the same infrastructure but burning more cleanly. Here are thee companies to watch.

3 Metaverse Stocks to Sell as They Fail to Deliver

By John Blankenhorn, InvestorPlace Contributor

The metaverse hasn't lived up to the hype, so don't get caught out when these metaverse stocks drop hard and fast as they fail to deliver.

Load More